title: Histopathology and bronchoalveolar lavage.
abstract: Although neither lung biopsy nor bronchoalveolar lavage (BAL) is recommended for routine clinical use in patients with SSc, studies employing lung biopsy material and BAL fluid (BALF) have provided insight into the pathogenesis of scleroderma-associated interstitial lung disease (SSc-ILD). Most often, SSc-ILD is classified as a non-specific interstitial pneumonia, with abundant myofibroblasts and evidence of both epithelial cell and endothelial cell injury. Recently, SSc-ILD fibroblasts have been shown to express reduced levels of the caveolin-1 protein which, in turn, may lead to activation of the signalling molecules associated with increased collagen production and overexpression of alpha-smooth muscle cell actin (alpha-SMA). BALF often contains increased numbers of inflammatory cells as well as myofibroblasts expressing alpha-SMA. Analysis of BALF suggests an imbalance between pro-fibrotic and anti-fibrotic factors, e.g. an overabundance of TGF-beta, connective tissue growth factor (CTGF), PDGF, leucotriene B4, etc. and in some cases a deficiency of hepatocyte growth factor, 15-hydroxyeicosatetraenoic acid (15-HETE), lipoxin A, etc. Until the pathogenesis is fully understood, lung biopsy and BAL will remain useful research tools to better understand the inflammatory and fibrosing processes that underlie SSc-ILD.
authors.affiliation: Department of Medicine, Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. silverr@musc.edu
authors.forename: R M
authors.initials: RM
authors.lastname: Silver
authors.forename: A U
authors.initials: AU
authors.lastname: Wells
mesh_terms: D001706:Biopsy; D018893:Bronchoalveolar Lavage; D006801:Humans; D008168:Lung / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000150:complications* / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000150:complications / Q000473:pathology; D012595:Scleroderma, Systemic / Q000150:complications* / Q000473:pathology; D012680:Sensitivity and Specificity
references.citation: Clin Exp Rheumatol. 2004 Nov-Dec;22(6):733-42
references.pmid: 15638048
references.citation: J Biol Chem. 2001 Nov 30;276(48):45184-92
references.pmid: 11579091
references.citation: Eur J Pharmacol. 2006 Mar 8;533(1-3):222-39
references.pmid: 16500642
references.citation: Arthritis Rheum. 1984 Nov;27(11):1254-62
references.pmid: 6497920
references.citation: Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8
references.pmid: 17901414
references.citation: Proc Am Thorac Soc. 2006 Jun;3(4):377-82
references.pmid: 16738204
references.citation: Arthritis Rheum. 2003 Aug;48(8):2262-74
references.pmid: 12905481
references.citation: Am J Med. 1990 May;88(5):470-6
references.pmid: 2337105
references.citation: Am J Physiol Lung Cell Mol Physiol. 2008 May;294(5):L843-61
references.pmid: 18203815
references.citation: Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):400-6
references.pmid: 8756813
references.citation: Arthritis Rheum. 2005 Dec;52(12):3783-91
references.pmid: 16320329
references.citation: Eur Respir J. 2007 Mar;29(3):446-52
references.pmid: 17107986
references.citation: Ann Rheum Dis. 2005 Sep;64(9):1343-6
references.pmid: 16100339
references.citation: Am J Respir Cell Mol Biol. 2007 Jul;37(1):38-47
references.pmid: 17379848
references.citation: Am J Respir Cell Mol Biol. 1994 Apr;10(4):405-12
references.pmid: 7510986
references.citation: Arthritis Rheum. 2007 Jul;56(7):2432-42
references.pmid: 17599773
references.citation: J Rheumatol. 1992 Nov;19(11):1716-23
references.pmid: 1491389
references.citation: J Exp Med. 2006 Dec 25;203(13):2895-906
references.pmid: 17178917
references.citation: Arthritis Rheum. 2007 Dec;56(12):4195-202
references.pmid: 18050251
references.citation: Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6
references.pmid: 12070056
references.citation: J Biol Chem. 2005 Apr 8;280(14):13879-87
references.pmid: 15691837